Tower Research Capital LLC (Trc) Adaptimmune Therapeutics PLC Transaction History

Tower Research Capital LLC (Trc)

$3.29 Billion
Q1 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 21,966 shares of ADAP stock, worth $1,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,966

Previous 19,530 12.47%

Holding current value

$1,757

Previous $10,000 60.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.2 - $0.65 $487 - $1,583	2,436 Added 12.47%	21,966 $4,000
Q4 2024 Feb 13, 2025	BUY	$0.54 - $0.95 $8,027 - $14,121	14,865 Added 318.65%	19,530 $10,000
Q3 2024 Nov 14, 2024	BUY	$0.92 - $1.39 $4,291 - $6,484	4,665 New	4,665 $4,000
Q4 2023 Feb 13, 2024	BUY	$0.43 - $0.79 $1,129 - $2,075	2,627 Added 32.69%	10,664 $8,000
Q3 2023 Nov 14, 2023	SELL	$0.73 - $1.04 $5,867 - $8,358	-8,037 Reduced 50.0%	8,037 $6,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $3,421 - $5,741	3,802 Added 30.98%	16,074 $14,000
Q1 2023 May 09, 2023	BUY	$1.06 - $2.16 $4,541 - $9,253	4,284 Added 53.63%	12,272 $13,000
Q4 2022 Feb 10, 2023	SELL	$1.05 - $2.53 $22,976 - $55,361	-21,882 Reduced 73.26%	7,988 $12,000
Q3 2022 Nov 10, 2022	BUY	$1.06 - $2.41 $515 - $1,171	486 Added 1.65%	29,870 $32,000
Q2 2022 Aug 15, 2022	BUY	$1.33 - $2.28 $32,812 - $56,249	24,671 Added 523.47%	29,384 $50,000
Q1 2022 May 12, 2022	SELL	$1.73 - $4.06 $2,101 - $4,932	-1,215 Reduced 20.5%	4,713 $10,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $11,028 - $17,897	-3,151 Reduced 34.71%	5,928 $22,000
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $16,646 - $30,824	4,839 Added 114.13%	9,079 $47,000
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $5,539 - $8,294	-1,435 Reduced 25.29%	4,240 $18,000
Q1 2021 May 17, 2021	BUY	$4.9 - $6.83 $14,660 - $20,435	2,992 Added 111.52%	5,675 $30,000
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $10,732 - $24,683	2,683 New	2,683 $14,000
Q2 2020 Aug 13, 2020	SELL	$2.58 - $12.1 $24,744 - $116,051	-9,591 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $11,314 - $42,619	9,429 Added 5820.37%	9,591 $26,000
Q4 2019 Feb 07, 2020	SELL	$0.72 - $1.43 $15,343 - $30,473	-21,310 Reduced 99.25%	162 $0
Q3 2019 Nov 05, 2019	BUY	$1.43 - $3.81 $30,561 - $81,427	21,372 Added 21372.0%	21,472 $32,000
Q2 2019 Aug 13, 2019	SELL	$3.23 - $5.41 $20,316 - $34,028	-6,290 Reduced 98.44%	100 $0
Q1 2019 May 14, 2019	BUY	$3.63 - $6.06 $23,195 - $38,723	6,390 New	6,390 $27,000
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $1,864 - $7,023	-496 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $12,115 - $19,865	-1,465 Reduced 74.71%	496 $7,000
Q2 2018 Aug 15, 2018	SELL	$10.42 - $13.74 $14,171 - $18,686	-1,360 Reduced 40.95%	1,961 $23,000
Q1 2018 May 15, 2018	SELL	$7.1 - $11.56 $10,657 - $17,351	-1,501 Reduced 31.13%	3,321 $37,000
Q4 2017 Feb 09, 2018	BUY	$6.68 - $8.74 $32,210 - $42,144	4,822	4,822 $32,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

115M

Call Options Held

77.5K

Put Options Held

14.2K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $13.1M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Adaptimmune Therapeutics PLC Transaction History